Skin testing not sufficient to ID contrast media sensitivity

Skin testing not sufficient to ID contrast media sensitivity
More than 50 percent of patients with nonimmediate reactions to iodinated contrast media are identified with the drug provocation test and not with skin testing, according to a study published online May 15 in Allergy.

(HealthDay) -- More than 50 percent of patients with nonimmediate reactions to iodinated contrast media (CM) are identified with the drug provocation test (DPT) and not with skin testing, according to a study published online May 15 in Allergy.

Maria J. Torres, M.D., Ph.D., of Carlos Haya Hospital in Malaga, Spain, and associates investigated the role of skin testing and the DPT in the diagnosis of nonimmediate reactions to CM in 161 patients. Skin intradermal and patch testing were performed with different CM. In cases with a negative skin test, a single-blind placebo-controlled DPT was performed.

The researchers found that 21.1 percent of the subjects were skin-test positive to the various CM. In 34.6 percent of skin-test negative cases the DPT was positive. Of the 78 cases with confirmed hypersensitivity, 56.4 percent were identified by DPT and 43.6 percent were identified by skin testing.

"We conclude that sensitivity is not sufficient and that, in more than 50 percent of cases, a DPT is also needed to establish the diagnosis," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

New national study links asthma to allergies

Sep 27, 2007

Researchers at the National Institutes of Health (NIH) have found that more than 50 percent of the current asthma cases in the country can be attributed to allergies, with approximately 30 percent of those cases attributed ...

Recommended for you

Structured education program beneficial for anaphylaxis

Nov 21, 2014

(HealthDay)—A structured education intervention improves knowledge and emergency management for patients at risk for anaphylaxis and their caregivers, according to a study published online Nov. 19 in Allergy.

Every step you take: STING pathway key to tumor immunity

Nov 20, 2014

A recently discovered protein complex known as STING plays a crucial role in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the body's innate immune system, according to two separate ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.